CAR-T cells for hard-to-treat neuromyelitis optica
Part of Immune system & allergy clinical trials.
This trial tests a special immune cell therapy (CAR-T) for people with a type of NMOSD that hasn't responded well to other treatments. The cells are made to target a protein called BCMA to help calm the immune attack on your nerves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have neuromyelitis optica spectrum disorder (NMOSD) that has not responded to other treatments
- You are expected to live at least 12 more weeks
- You agree to use effective birth control during the study and for one year after treatment (if you are able to become pregnant or father a child)
- You do not have a history of organ transplant, recent cancer, certain active infections (like hepatitis B, C, HIV, or CMV), severe heart disease, or serious psychiatric conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a universal CAR-T cell treatment for people with autoimmune diseases of the nervous system that haven't responded to standard therapies. It aims to see if this therapy can help control diseases like neuromyelitis optica, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multiple sclerosis.
This trial tests an experimental cell therapy (BAFFR CAR T cells) for people with neuromyelitis optica spectrum disorder (NMOSD) who have not responded well to standard treatments. It aims to see if these cells can help reduce relapses and improve symptoms by targeting a specific immune cell receptor.
This trial tests a treatment called CNCT19, a type of CAR-T cell therapy, for people with certain autoimmune diseases like neuromyelitis optica, myasthenia gravis, or multiple sclerosis that have come back or not responded to other treatments. It aims to see if targeting a specific immune cell (CD19) can help control the disease.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This early-stage trial tests a new type of immune cell therapy (CAR T-cells) against several relapsed or hard-to-treat autoimmune diseases that affect the nervous system. The goal is to see if this treatment can safely calm the immune system and improve symptoms.
Hear when a new Autoimmune Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.